Clinical trials: Pancreatic Mass
Type 2 Diabetes
Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls
To evaluate 18F-AV-133 imaging of the pancreas in patients with early type 2 diabetes, late type 2 diabetes, subjects with pre-diabetes and in healthy overweight/obese control subjects.
- Trial name
- NCT01710371
- Testing
- 18F-AV-133, 10% Arginine Hydrochloride-R-Gene 10
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Breast Cancer, Benign Breast Condition
ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health
AUDIBLE is a multi-site, clinical study conducted in the United States aimed at gathering data on 3D Automated Breast Ultrasound imaging using the iSono Health ATUSA system.
- Conditions
- Breast Cancer, Benign Breast Condition, Breast Fibroadenoma, Breast Neoplasms
- Trial name
- AUDIBLE (NCT07505797)
- Testing
- ATUSA 3D Automated Breast Ultrasound System
- Where
- 2 sites in United States
- Volunteers
- 800 people
- Sponsor
- iSono Health, Inc.
Pancreatic Cyst, Pancreatic Neoplasms
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
This study focuses on four different lesions: pancreatic cysts, lymph nodes near the gastrointestinal tract, pancreatic masses and GIST tumors.
- Conditions
- Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Adenoma, Pancreatic Cancer
- Trial name
- US-nCLE (NCT01770405)
- Testing
- Endoscopic ultrasound fine needle aspiration
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mauna Kea Technologies
Advanced Cancer
C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
This is an open-label study being conducted to determine the metabolism and physiological disposition of radiolabeled LY2603618 after a single dose in patients with advanced and/or metastatic solid tumors.
- Trial name
- NCT01296568
- Testing
- LY2603618, Pemetrexed, Gemcitabine
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.
Assess pancreatic beta cell function using MR imaging.
- Trial name
- NCT00280085
- Testing
- MR imaging, Glucose clamp, Arginine
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pancreatic Cyst, Pancreatic Neoplasms
Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
This study focuses on three different lesions: pancreatic cysts, lymph nodes near the gastrointestinal tract and pancreatic masses.
- Conditions
- Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Adenoma, Pancreatic Cancer
- Trial name
- CONTACT (NCT01563133)
- Testing
- EUS-FNA, nCLE
- Where
- 3 sites in France
- Volunteers
- 330 people
- Sponsor
- Mauna Kea Technologies
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Pancreatic Cancer, Metastatic Breast Cancer
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment.
- Conditions
- Pancreatic Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Colon Cancer
- Trial name
- NCT03073473
- Testing
- NantHealth GPS Cancer Test
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cota Inc.
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study Looking at Whether a Nutritional Composition Can Help People With Pancreatic Cancer Stay Stronger and Better Tolerate Chemotherapy
The HEXCARE-PDAC study is a Phase III, randomized, double-blind, controlled, multicenter trial evaluating the effectiveness of a cancer-specific oral nutritional supplement in preserving skeletal muscle mass and improving…
- Trial name
- HEXCARE-PDAC (NCT07870421)
- Testing
- A novel cancer-specific high energy high protein medical nutrition solution, A commercially available isocaloric isonitrogenous medical nutritional solution.
- Volunteers
- 216 people
- Sponsor
- Nutricia Research
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Pancreatic Cancer, Bile Duct Cancer
A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers
This registry will collect data from patients routinely undergoing an ERCP and Cellvizio endomicroscopy procedure (and optionally an additional cholangiopancreatoscopy procedure) due to suspected pancreatic or bile duct cancer.
- Trial name
- NCT00779688
- Testing
- Probe-based confocal laser endomicroscopy
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 130 people
- Sponsor
- Mauna Kea Technologies
Non-Small Cell Lung Cancer, Metastatic Melanoma
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
The aims of this Study were to determine: How much of the Study Drug (bemcentinib) ends up in urine and faeces How much of the Study Drug and its breakdown products get into the bloodstream The breakdown products (metabolites) of…
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- 8479217 (NCT06469138)
- Testing
- Bemcentinib
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA